Lowest Price Guaranteed
Pages
320
Last Updated
July 2026
View Count
15025
The global stem cell manufacturing market for contract manufacturers is estimated to grow from USD 76 million in 2026 to USD 279 million by 2035. It is anticipated to grow at a healthy CAGR of 15.6% during the forecast period.
 |
To learn more about this report, request a free sample copy
The growth of the market is attributed to the increasing demand for stem cells in regenerative therapies and cancer treatment.
Stem cell therapy is amongst the novel treatment modalities being considered as a groundbreaking medical treatment to repair and regenerate damaged cells and tissues due to disease. These cells, referred to as pluripotent stem cells, have been derived from body parts, including bone marrow, skin, blood vessels, brain, and heart. The embryonic stem cells are obtained from the inner cell mass of a blastocyst, an early-stage pre-implantation embryo. Stem cells have the potential to divide and differentiate into tissues and cells that can be used to repair as well as replace damaged cells. Advances in cellular biology, biotechnology, and stem cell research have led to the development of stem cell therapies to treat a wide range of diseases including cardiovascular diseases, musculoskeletal disorders, and oncological disorders.
It is important to highlight here that cancer and chronic diseases have been a major cause of concern worldwide, driven by the rising incidences of cases. According to the report of the National Institute of Health, in 2024, nearly 2,001,140 new cases of cancer have been diagnosed, and around 611,720 deaths have been projected to occur in the US due to cancer. Further, the report of the Centered for Disease Control and Prevention estimates that in 2024, around 129 million people in the United States will have one or more chronic diseases, including diabetes, hypertension, obesity, and cancer. People with chronic disease suffer from pain issues due to damaged tissues and cells with disease conditions. Stem cell therapy can help patients by repairing and replacing damaged cells and tissues, managing pain that negatively impacts their lives.
 |
 |
 |
Furthermore, stem cell therapies have played a significant role as regenerative medicine to treat patients with spinal cord injuries, amyotrophic lateral sclerosis, heart disease, stroke, burn, osteoarthritis, and Alzheimer's disease. Driven by the increasing usage of stem cell therapies, the regenerative medicine market is estimated to generate revenues worth USD 100 billion by 2030. It is interesting to note here that the significance offered by stem cells in repairing or replacing damaged cells has catered to the attention of several researchers and pharmaceutical companies active in this field. Currently, more than 200 stem cell therapy candidates are being evaluated under the clinical pipeline.
The growing research on stem cell therapies has attracted the attention of the pharmaceutical companies active in this domain to develop advanced stem cell therapeutic interventions to target a broad range of diseases. However, manufacturing stem cell therapies requires state-of-the-art technologies and a highly regulated environment, which is difficult to establish within in-house manufacturing capacities. As a result, various stem cell therapy developers continue to outsource their operations from contract manufacturing organizations (CMOs). In particular, small and mid-sized developers intend to outsource a substantial proportion of clinical and commercial-scale stem cell therapy manufacturing to CMOs. Considering the outsourcing trend, we believe that the stem cell manufacturing market is estimated to grow at a higher pace during the forecast period, driven by the robust pipeline of stem cell therapeutic interventions, ongoing research, and increasing collaborations.
The market report covers an in-depth analysis of various companies that are active in the global stem cell manufacturing industry across different segments, as defined in the table below.
| Key Report Attributes | Details | |
| Historical Trend | Since 2019 | |
| Base Year | 2025 | |
| Forecast Period | 2026-2035 | |
| Market Size 2035 | USD 279 Million | |
| Distribution by Source of Stem Cells |
|
|
| Type of Stem Cells |
|
|
| Scale of Operation |
|
|
| Key Geographical Region |
|
|
| Key Companies Profiled |
|
|
| PowerPoint Presentation (Complimentary) |
Available | |
| Customization Scope | 15% Free Customization | |
| Excel Data Packs (Complimentary) |
|
|
The key objective of the market report is to provide detailed stem cell manufacturing market analysis in order to estimate the existing market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics, and future opportunities during the forecast period. Based on parameters such as an increase in the number of clinical studies, target patient population, anticipated adoption of stem cell therapies, and expected variation in manufacturing costs, we have provided an informed estimate of the likely evolution of the market in the mid to long term, for the forecast period Till, 2035.
 |
 |
 |
In order to provide a detailed future outlook, our projections have been segmented on the basis of [A] source of stem cells (autologous and allogenic), [B] types of stem cells (adult, embryonic and induced pluripotent), [C] size of contract service provider company (small-sized, mid-sized and large), [D] scale of operation (preclinical, clinical and commercial) and [E] key geographical regions (North America, Europe and Asia and rest of the world). To account for the uncertainties associated with the manufacturing of stem cell therapies and to add robustness to our model, we have provided three market forecast scenarios, portraying the conservative, base, and optimistic tracks of the market's evolution.
The opinions and insights presented in the market report were influenced by discussions held with senior stakeholders in the industry. The market research report features detailed transcripts of interviews held with the following industry stakeholders:
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market report are in USD, unless otherwise specified.
The global stem cell manufacturing market has been segmented into autologous and allogenic based on the source of cells. According to our projection, the autologous market segment accounts for the highest share and is poised to capture 64.9% of overall revenue share by 2035. This can be attributed to the fact that autologous stem cells have been directly derived from the patient body which further reduces the risk of immune cell rejection. Therefore, autologous are widely applicable for the development of personalized therapies. However, in the future, allogenic based sources will expand at a higher CAGR of 22.4% during the forecast period. This highest growth potential is likely to be the result of wider applicability of allogenic stem cells in treating patients. Moreover, allogenic stem cells are easy to scale up, making it ideal for large scale production.
Based on the type of stem cells, the market has been segmented into adult, embryonic, and induced pluripotent cells. In terms of stem cell types, currently our authors predicted that adult stem cell accounts for the highest share of the market and are estimated to capture 78% of overall revenue share by 2035. This can be attributed to the fact that adult stem cells are widely used in therapy’s development and research areas. Furthermore, these cells are easy to procure and there is high demand for adult stem cells for tissue engineering. However, in the long run, induced pluripotent cells will grow at a higher CAGR of 36% during the forecast period. This can be attributed to differentiating ability of induced pluripotent cells into any cell type that makes it ideal for disease modeling, drug screening and research.
The global market has been segmented into preclinical, clinical, and commercial segment on the basis of scale of operation. According to our projection, currently the commercial segment accounts for the highest stem cell manufacturing market share and is poised to capture 81.84% of the revenue share by 2035. This dominance is due to the growing demand for stem cell therapies at commercial level and increasing transition from market-ready products that require upscaling. Driven by the ongoing demand, the commercial segment will continue to grow at a higher CAGR of 26% during the forecast period.
The global stem cell manufacturing market is currently distributed across North America, Europe, Asia-Pacific and the rest of the world. According to our projection, currently North America accounts for the highest share of the market and is anticipated to capture 37% of the overall revenue share by 2035. This is likely to be the result of the presence of well-established pharmaceutical companies who are currently emphasizing the production of advanced stem cell therapies. It is important to highlight here that dominance will continue to remain unchanged and this region will grow at a higher CAGR of 19% during the forecast period.
The “Global Stem Cell Manufacturing Market: Industry Trends and Global Forecasts, Till 2035” market report features an extensive study on current market landscape, market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics and future opportunities of the stem cell manufacturing industry.
Driven by the increasing research on stem cell therapies, the demand for contract manufacturing services has been fueled. Currently, the stem cell manufacturing market landscape features the presence of more than 80 companies with the required technological capabilities to support the manufacturing of stem cell therapies. Overall, the market has the presence of well-established, small, mid-sized, and large players operating at different scales of operation and providing various technological support as well as skilled personnel support for manufacturing a diverse range of stem cell therapies. The established global stem cell therapy contract manufacturing capacities are estimated to spread across over 100 facilities worldwide.
Driven by the growing incidence of chronic diseases, there is a surge in the demand for stem cell therapies. Stem cells, particularly mesenchymal stem cells, and induced pluripotent stem cells possess the ability to divide into different cell types, making them an excellent tool for treating injuries and diseases that result in damaged cells and tissues. Furthermore, the increasing emphasis on regenerative medicine for tissue regeneration has become a key driver of the stem cell manufacturing market. Presently, stem cell-based regenerative therapies are being evaluated in clinical studies to restore damaged specialized cells in patients with serious diseases such as neurodegenerative diseases, Alzheimer's, and spinal cord injuries. For instance, In February 2023, a new stem cell therapy transplant developed at Lund University in Sweden achieved a milestone in treating patients with Parkinson’s disease (PD). The therapy was given for the first time to humans with Parkinson’s disease, and it has been designed for the replacement of lost dopamine cells. Stem cell therapy delivers functional dopamine cells: ventral midbrain dopaminergic progenitor cells derived from stem cells, clinical grade hESC line RC17. The rising focus on regenerative medicine and stem cell therapies for neurodegenerative disorders is likely to fuel the stem cell manufacturing market growth in the coming years.
Given that stem cell therapy manufacturing requires highly regulated, state-of-the-art technologies, it is difficult for stakeholders to establish in-house expertise for large-scale manufacturing of stem cell therapies. As a result, stem cell therapy developers have begun outsourcing their manufacturing operations to contract manufacturing organizations (CMOs). Specifically, small and mid-sized players in this sector tend to outsource a substantial proportion of clinical and commercial-scale manufacturing processes to contract service providers. In addition, even big pharma players, with established in-house capabilities, are gradually entering into long-term business relationships with CMOs in order to optimize resource utilization and manage costs.
Stem cells have shown significant traction owing to ongoing research and clinical trials targeting diseases. Despite enormous growth opportunities, the stem cell manufacturing market has witnessed several challenges that will impede its growth in the future. Some of the biggest challenges involve the high cost associated with manufacturing and banking of stem cell therapies. Scaling up of stem cell lines requires advanced technological support to maintain optimal growth conditions, which enhances the overall expenditure of stem cell therapy. Furthermore, stem cell therapies require special banking infrastructure and cold storage units along with skilled personnel support, which further enhances their overall operational cost. In addition to high cost, stem cell manufacturing requires adherence to standardized protocols provided by regulatory agencies for stem cell types such as mesenchymal stem cells and erythropoietin-producing cells that will be utilized in regenerative medicine therapies.
The market for stem cell manufacturing is expected to grow at a steady pace owing to the expanding research on regenerative medicine to use stem cells in a wide range of applications such as tissue engineering, disease modeling, and drug discovery. Further, stem cell developers are adopting advanced technologies such as 3D bioprinting and CRISPR gene editing technology that enable the production of innovative stem cell-based therapies. Regulatory agencies are providing flexibility in guidelines and protocols for stem cell manufacturing, ensuring effective and safe use of stem cell-based therapies. The growing usage of stem cell therapies as regenerative medicine is attracting venture capital and pharmaceutical firms’ interest to make considerable investments in technological advancements that support stem cell manufacturing. For instance, in May 2023, StemCures (US Based Stem Cell Manufacturing Company) announced a capital investment of USD 54 million to establish the largest stem cell manufacturing laboratory in India. Driven by the growing investment in the field and rising acceptance of new technologies along with progress in regulatory guidelines, the stem cell manufacturing market is expected to grow in the coming years.
The stem cell manufacturing market is currently valued at USD 76 million and is poised to reach USD 279 million by 2035. This lucrative growth potential is likely to be the result of growing demand for advanced target specific therapies for the treatment of chronic diseases. However, it is important to highlight here that stem cell manufacturing demands specialized infrastructure to maintain a sterile and temperature-controlled environment. Owing to the requirement of specialized manufacturing conditions, several leading stem cell therapy developers are inclining towards third party manufacturing services. Driven by the growing shift towards outsourcing, the market for stem cell manufacturing is likely to grow at a higher CAGR of 15.6% during the forecast period till 2035.
Examples of key stem cell contract manufacturing companies engaged in stem cell manufacturing industry (which have also been profiled in this market report; the complete list of stem cell CMOs is available in the full report) include BioNTech Innovative Manufacturing Services, Cell and Gene Therapy Catapult, FUJIFILM Cellular Dynamics, GenCure, Lonza, MEDINET, Nikon CeLL innovation, Progenitor Cell Therapy (PCT), Roslin Cells, Waisman Biomanufacturing, and WuXi Advanced Therapies. This market report includes an easily searchable excel database of all the stem cell contract manufacturing companies worldwide.
Several recent developments have taken place in the field of stem cell manufacturing. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.
The “Stem Cell Manufacturing Market, till 2035” market report features an extensive study of the current market landscape, market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics, and future opportunities of the stem cell manufacturing market. The market research report features in-depth analyses, highlighting the capabilities of various stem cell therapy CMOs.
Amongst other elements, the market research report includes: